Stock Research for ABT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABT Stock Chart & Research Data

The ABT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABT Due diligence Resources & Stock Charts

The ABT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABT Detailed Price Forecast - CNN Money CNN View ABT Detailed Summary - Google Finance
Yahoo View ABT Detailed Summary - Yahoo! Finance Zacks View ABT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABT Trends & Analysis - Trade-Ideas Barrons View ABT Major Holders - Barrons
NASDAQ View ABT Call Transcripts - NASDAQ Seeking View ABT Breaking News & Analysis - Seeking Alpha
Spotlight View ABT Annual Report - CompanySpotlight.com OTC Report View ABT OTC Short Report - OTCShortReport.com
TradeKing View ABT Fundamentals - TradeKing Charts View ABT SEC Filings - Bar Chart
WSJ View Historical Prices for ABT - The WSJ Morningstar View Performance/Total Return for ABT - Morningstar
MarketWatch View the Analyst Estimates for ABT - MarketWatch CNBC View the Earnings History for ABT - CNBC
StockMarketWatch View the ABT Earnings - StockMarketWatch MacroAxis View ABT Buy or Sell Recommendations - MacroAxis
Bullish View the ABT Bullish Patterns - American Bulls Short Pains View ABT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABT Stock Mentions - StockTwits PennyStocks View ABT Stock Mentions - PennyStockTweets
Twitter View ABT Stock Mentions - Twitter Invest Hub View ABT Investment Forum News - Investor Hub
Yahoo View ABT Stock Mentions - Yahoo! Message Board Seeking Alpha View ABT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABT - SECform4.com Insider Cow View Insider Transactions for ABT - Insider Cow
CNBC View ABT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABT - OTC Markets
Yahoo View Insider Transactions for ABT - Yahoo! Finance NASDAQ View Institutional Holdings for ABT - NASDAQ


Stock Charts

FinViz View ABT Stock Insight & Charts - FinViz.com StockCharts View ABT Investment Charts - StockCharts.com
BarChart View ABT Stock Overview & Charts - BarChart Trading View View ABT User Generated Charts - Trading View




Latest Financial News for ABT


See what the IHS Markit Score report has to say about Abbott Laboratories.
Posted on Saturday October 20, 2018

Abbott Laboratories NYSE:ABT


Thermo Fisher: Analysts’ Estimates and Recommendations
Posted on Friday October 19, 2018

Wall Street analysts expect Thermo Fisher Scientific’s (TMO) third-quarter revenues to increase ~11.5% to $5.7 billion—compared to its revenues of $5.1 million during the third quarter of 2017. The adjusted EPS is estimated to be $2.55 for the third quarter—compared to the adjusted EPS of $2.31 in the third quarter of 2017.


Gauging Analysts’ Views for NovoCure Stock
Posted on Friday October 19, 2018

Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.


NovoCure’s Operational Performance in Q3 2018: What to Expect
Posted on Friday October 19, 2018

NovoCure’s (NVCR) gross income is expected to rise 28.22% to $44.82 million in the third quarter of 2018. Its gross margin is expected to contract from 69.76% in the third quarter of fiscal 2017 to 68.7% in the third quarter of fiscal 2018. NovoCure’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 67.97% and 72.72%, respectively.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.